Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | PTPRC | P08575 | 2/20 | 0.37 |
| ▸ | PTPRF | P10586 | 2/20 | 0.37 |
| ▸ | CDC25B | P30305 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21113725 | 0.82 | PTPN1 (0.52) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL19547127 | 0.78 | PTPN1 (0.37) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL28887375 | 0.78 | PTPN1 (0.34) | PTPN1PTPRCPTPRFCDC25BMEN1 | |
| SCHEMBL727947 | 0.78 | PTPN1 (0.34) | PTPN1PTPRCPTPRFCDC25BMEN1 | |
| Hydrochloric Acid SCHEMBL4450657 | 0.77 | PTPN1 (0.36) | PTPN1PTPRCPTPRFCDC25BMEN1 | |
| Hydrochloric Acid SCHEMBL994817 | 0.77 | PTPN1 (0.36) | PTPN1PTPRCPTPRFCDC25BMEN1 | |
| SCHEMBL4454087 | 0.74 | — | — | |
| SCHEMBL14995044 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL727675 | 0.73 | — | — | |
| Biphenyl SCHEMBL28193720 | 0.73 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| EP-2310396-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-06 | — | — | EP | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| WO-2017064680-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SIMEPREVIR SODIUM AND INTERMEDIATE THEREOF | LUPIN LIMITED (IN) | 2017-04-20 | — | — | WO | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen Sciences Ireland Unlimited Company (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9365582-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-14 | — | — | US | disclosed |
| US-9353103-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-31 | — | — | US | disclosed |
| US-9334282-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-10 | — | — | US | disclosed |
| WO-2008135488-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-10-23 | — | — | US | disclosed |
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008096001-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095999-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096002-A1 | HCV INHIBITING MACROCYCLIC PHOSPHONATES AND AMIDOPHOSPHATES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008092955-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008059046-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-05-22 | — | — | WO | disclosed |
| EP-1912997-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007014925-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | PTPN1 1327/4885PTPRC 1244/4885PTPRF 2860/4885 |
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, EIF2AK2 | PTPN1 1937/4885PTPRC 567/4885PTPRF 1030/4885 |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | PTPN1 1327/4885PTPRC 1244/4885PTPRF 2860/4885 |
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | HAVCR2, HCCS, CYP7A1 | PTPN1 1347/4885PTPRC 1414/4885PTPRF 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.